LEMAITRE VASCULAR INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $LMAT in the last 7 days.
No SEC Form 4 filings for $LMAT in the last 30 days.
See all $LMAT insider activity →Baxter (BAX) reported Q2 revenue of $2.96B, up 5.3% YoY, beating estimates. LeMaitre (LMAT) reported $70.38M, up 9.6% YoY, missing estimates. STERIS (STE) reported $1.49B, up 7.3% YoY, in line with estimates. Lantheus (LNTH) reported $388.2M, up 2.7% YoY, beating estimates. Stocks are down since reporting.
Hedge funds reduced long positions in Amazon, Tesla, Meta, Alphabet, and Apple in August, while increasing shorts in Amazon, Alphabet, and Apple. AI debt financing raised concerns about future cash flows. Nvidia saw a decline in short interest. MACOM Technology Solutions shifted from short to long bias. Semiconductor sector sentiment turned modestly less bullish, with Applied Materials, Nvidia, and Lam Research seeing the most long crowding.
Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.
Recent LMAT coverage spans earnings, sector analysis and financial news.
No fresh news; market has priced the miss and guidance downgrade.
Higher short interest may depress the stock.
Missed expectations and weak guidance likely keep pressure on the stock.
Earnings and guidance disappointment around Artegraft launch and RFA setup appears to be the key near-term negative catalyst for LMAT.
Guidance and margin expansion, plus Artegraft growth, are likely to drive near-term sentiment, while cardiac allograft supply constraints and export delays are key offsets.
AlphAI scores every news story that mentions LMAT with an AI model for sentiment and relevance, and aggregates insider trades from LEMAITRE VASCULAR INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Baxter (BAX) reported Q2 revenue of $2.96B, up 5.3% YoY, beating estimates. LeMaitre (LMAT) reported $70.38M, up 9.6% YoY, missing estimates. STERIS (STE) reported $1.49B, up 7.3% YoY, in line with estimates. Lantheus (LNTH) reported $388.2M, up 2.7% YoY, beating estimates. Stocks are down since reporting.
2 min readHedge funds reduced long positions in Amazon, Tesla, Meta, Alphabet, and Apple in August, while increasing shorts in Amazon, Alphabet, and Apple. AI debt financing raised concerns about future cash flows. Nvidia saw a decline in short interest. MACOM Technology Solutions shifted from short to long bias. Semiconductor sector sentiment turned modestly less bullish, with Applied Materials, Nvidia, and Lam Research seeing the most long crowding.
3 min readIntegra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.
3 min readA specialty-stocks earnings recap compares Q2 results for LeMaitre (LMAT), Teleflex (TFX), Integra LifeSciences (IART), and Intuitive Surgical (ISRG). The group’s revenues beat consensus by 0.8%, but next-quarter guidance was 1.6% below. LMAT revenue was $70.38M (+9.6%) but missed by 1.7% and EPS. TFX revenue was $570.3M (+28.9%) beat by 2%. IART revenue $418.8M flat, in line. ISRG revenue $2.89B (+18.5%) beat by 2.6%.
7 min readLeMaitre Vascular (LMAT) reported Q2 2026 revenue of $70.4 million, up 10% organically, with diluted EPS of $0.74 (+23%). Gross margin rose to 72.1%. Artegraft sales grew 34% and now 21% of sales, while catheter sales fell 11%. Full-year guidance: revenue $274.3M-$278.3M, EPS $2.84-$2.94.
6 min readSimply Wall St reports LeMaitre Vascular (LMAT) released Q2 2026 results with higher sales and net income, updated guidance, and a reaffirmed cash dividend. It notes the stock’s recent 7-day and 30-day returns of about 21% and 21% versus 3- and 5-year TSR near 48% and 52%. It cites a fair value of $118.75 versus a last close of $81.45 and a P/E of 28.4x.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter discussed LeMaitre Vascular (NASDAQ:LMAT), citing 10% organic revenue growth, 72.1% gross margins, and adjusted EPS of $0.68 versus $0.66 consensus. Despite strong fundamentals, LMAT shares fell after earnings as investors took profits. LMAT closed Aug. 5 at $79, with a $1.81B market cap.
4 min readA market movers roundup highlights five stocks. LeMaitre (LMAT) fell 18.6% after Q2 results missed expectations and forecast was weak. ePlus (PLUS) dropped 5.1% despite Q2 2026 beating estimates. Booking (BKNG) rose 6.6% on Q2 results above estimates. Paymentus (PAY) fell 9.2% on cautious Q2 narrative. Vishay Intertechnology (VSH) slid 8.8% after mixed Q2 results, with revenue missing.
2 min readLeMaitre Vascular (NASDAQ: LMAT) shares fell 18.6% after Q2 results missed expectations and guidance weakened. Revenue was $70.38M vs $71.61M consensus, EPS was $0.74 vs $0.81. Q3 revenue guidance was $67.3M, about 3% below estimates, and full-year revenue was cut to $276.3M from $280M.
4 min readLeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2026 revenue of $70.38 million, up 9.6% year on year but below Wall Street estimates. Next-quarter revenue guidance was $67.3 million, about 3% under analysts’ expectations. GAAP EPS was $0.74, 8.3% below consensus. The stock fell 11.6% to $93.53 after results.
4 min read
